CytomX Therapeutics (NASDAQ:CTMX) & Generate Biomedicines (NASDAQ:GENB) Head-To-Head Review

Generate Biomedicines (NASDAQ:GENB) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Generate Biomedicines and CytomX Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1	1	6	0	2.62
CytomX Therapeutics	1	1	9	1	2.83

Generate Biomedicines currently has a consensus target price of $26.40, suggesting a potential upside of 90.82%. CytomX Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 472.79%. Given CytomX Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Generate Biomedicines.

Insider and Institutional Ownership

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Generate Biomedicines and CytomX Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89 million	55.68	-$203.15 million	($1.59)	-8.70
CytomX Therapeutics	$14.03 million	32.54	-$17.37 million	($0.50)	-4.19

CytomX Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Generate Biomedicines and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
CytomX Therapeutics	-608.98%	-33.97%	-27.19%

Summary

CytomX Therapeutics beats Generate Biomedicines on 9 of the 14 factors compared between the two stocks.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies.